Michael “Mick” Farrell was appointed ResMed’s CEO and has served as a director since March 2013. In January 2023, he was appointed chair of our board of directors. Mick joined the company in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and various senior roles in marketing and business development.
Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, DowDuPont, and BHP.
Mick serves on the board of directors of the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a global provider of implantable musculoskeletal medical devices. He is a member of two committees at Zimmer Biomet: the compensation and management development committee, as well as the quality, regulatory, and technology committee, of which he is chair. Mick also volunteers as a trustee for non-profit organizations: UC San Diego Foundation, Rady Children’s Hospital, and Father Joe’s Villages’ project for the homeless in San Diego, California.
Mick holds a bachelor of engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology, and a Master of Business Administration from the MIT Sloan School of Management.
Brett Sandercock was appointed chief financial officer in January 2006. Previously, he served as ResMed’s vice president of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004.
Before joining ResMed, Brett was manager of financial accounting and group reporting at Norton Abrasives, a division of Saint-Gobain, a French multinational corporation, from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients across distribution and manufacturing, financial services, technology, and other industries.
From June 2019 to August 2021, he has served as non-executive chairman of the board of directors of Osteopore Limited (ASX: OSX), an Australian- and Singapore-based medical technology company, commercializing products used for the regeneration of bone across a range of therapeutic areas.
Brett holds a Bachelor degree in economics from Macquarie University in Sydney, and is a certified chartered accountant.
Michael Rider was appointed Chief Legal Officer in July 2023. In his current role, Mike guides global legal strategy on a range of issues including intellectual property management; antitrust, anti-kickback, and other legal risks; corporate governance; acquisitions; privacy; and litigation. He previously served as ResMed’s senior vice president, deputy global general counsel, and legal business partner for ResMed’s Sleep & Respiratory Care team from July 2019 through June 2023, and before that as ResMed’s vice president and general counsel-Americas upon joining ResMed in June 2012.
Mike has nearly 40 years of legal experience. Prior to joining ResMed, he served as senior vice president, general counsel for Callaway Golf (NYSE: MODG), senior attorney for American Airlines (NASDAQ: AAL), and as a litigation associate at Gibson Dunn & Crutcher.
Mike graduated magna cum laude from the University of San Diego School of Law, served as executive editor of the San Diego Law Review, received its Distinguished Alumni Award in 2007, and currently serves on the USD School of Law Board of Visitors. He is also an executive committee member of the Corporate Directors Forum. Mike earned a Bachelor of Science in Pharmacy from the University of Arizona.
Bobby Ghoshal was appointed Chief Commercial Officer, SaaS, in August 2021. He previously served as ResMed’s chief technology officer; chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care; and leader of the information technology function for ResMed’s US, Canada, and Latin America commercial teams.
Bobby has more than 25 years’ experience in technology across multiple industries including finance, semiconductors and healthcare, working for companies including Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Bobby has helped build and lead high-performance teams in information technology, semiconductor innovation, digital and business strategy, information security, advanced analytics, operations and customer care.
Bobby holds a Master of Business Administration degree from Arizona State University and a bachelor’s degree in electronics engineering and telecommunications from the National Institute of Technology (NIT) in Calicut, India.
Katrin Pucknat was appointed ResMed Chief Marketing Officer in November 2023, responsible for strengthening ResMed’s brand and customer experience. She oversees overall brand efforts, communications, corporate marketing, and regional/performance marketing. Katrin previously served as President of Germany, leading the umbrella organization ResMed Germany Inc, whose subsidiaries are ResMed Healthcare (ResMed GmbH & Co. KG and ResMed Medizintechnik GmbH) and the specialist trade business of ResMed Deutschland GmbH.
Katrin is passionate about building high performing global teams. She has extensive experience in digital and business transformation and leading organizations through change.
Katrin has over 20 years’ experience in the medical device industry with a strong focus on digital health innovation and, in July 2021, was appointed Vice Chair on DIGITALEUROPE’s Executive Council for Health. She has held various leadership roles in ResMed, dating back to when she joined the company in 2010. Previously, she was CEO of ResMed Healthcare Germany; and director of European Marketing, Sleep & Diagnostics, responsible for the sleep-related respiratory disorders business in Europe.
Prior to joining ResMed, Katrin spent over 10 years in the United States with medical device companies focusing on marketing, communications, business innovation, and business development. She holds a bachelor’s degree in business and marketing.
Justin Leong was appointed ResMed Chief Product Officer in November 2023 and is responsible for building a portfolio of products, services, businesses, business models, and customer experiences on a global scale. He oversees product management, hardware and software engineering, commercial transformation, disruptive growth innovation and new business creation, user experience (UX) and customer experience (CX) design, product operations, product strategy, product marketing, and business development and partnerships. He is also a director on the board of various ResMed subsidiaries. Justin previously served as president of ResMed’s Asia and Latin American markets.
Justin’s prior positions with ResMed include serving as president of Asia Growth Markets, senior vice president, and general manager of greater China. He joined ResMed as vice president of Global Strategy in 2013.
Before joining ResMed, Justin was a director at London-based private equity firm HgCapital from 2006 to 2012, responsible for acquisitions and portfolio management, and serving on the board of directors of several European healthcare companies. From 1999 to 2004, he was a management consultant with Bain & Co. in Sydney, Boston, and New York, where he advised clients on growth strategies, operational improvement projects, mergers and acquisitions.
Justin holds a Bachelor of Commerce and a Bachelor of Laws from the University of New South Wales, Sydney, and a Master of Business Administration from the Harvard Business School.
Michael Fliss was appointed ResMed Chief Revenue Officer in November 2023, responsible for driving profitable revenue performance and growth. He oversees global sales, customer support, sales operations and enablement, and market access for the company. Michael previously served as VP of North American sales.
Michael has over 20 years of experience in sales with ResMed, having led several sales organizations within the company during his career ascent. He started out as a territory manager in March 2002 and moved up through the ranks as a corporate account manager, region manager, director, and area vice president before achieving his most recent role as VP of North American sales.
In addition to his daily duties, Michael serves as a board member for the LEANIn Sales employee resource group. He also has mentored for WOMEN Unlimited, Inc., and coached youth football, lacrosse and soccer.
Michael graduated from Canisius University with a bachelor of science degree in economics.
Dawn Haake was appointed ResMed’s Chief Quality Officer in May 2023. She previously served as ResMed’s vice president of quality assurance since 2015, adding vice president of regulatory affairs to her title in 2017, and combining them as vice president, quality assurance and regulatory affairs in 2018. Her duties include guiding and overseeing quality and safety processes related to ResMed’s sleep and respiratory care devices, device-related digital solutions, and health IT solutions for B2B SaaS customers – as well as regulatory requirements and related policies in each of the 140-plus countries ResMed serves.
Dawn has over 30 years’ experience in the medtech industry. Previously she was senior director of global quality assurance at NuVasive (NASDAQ: NUVA), senior specialist of quality assurance/CAPA at Nellcor Puritan Bennett (now owned by Medtronic (NYSE: MDT)), and tech support administrator at Infrasonics, Inc., a market leader in critical care ventilation.
Dawn serves as board secretary for Twin Oaks Valley Equestrian Association and board secretary for the Horse Heritage Conservancy, a 501(c)(3) land conservancy in San Diego County.
Dawn holds a bachelor’s in medical quality management systems from the University of Massachusetts Amherst and an Associate of Science in mathematics and science from Palomar College in San Marcos, California.
Vered Keisar was appointed ResMed Chief People Officer in March 2021, responsible for driving the company's global culture and People strategy. She previously served as vice president and General Counsel for ResMed's Asia and Latin America regions.
Vered has over 25 years of broad industry experience ranging from healthcare and pharmaceuticals to defense and insurance. Before joining ResMed in 2012, she worked in leading law firms in the UK, Australia, Japan, and Israel.
Vered is qualified to practice law in England and Wales, Australia, and Israel. She has an MBA from the Sydney Graduate School of Management, a Diploma of Laws in European Competition Law from King's College in London, and a Bachelor of Laws from the College of Management Academic Studies in Israel.
From 2016 to 2020, Vered was the elected chairperson of the Australian Diversity and Inclusion Committee for the Association of Corporate Counsel, the world's largest organization dedicated to in-house counsel, with more than 45,000 members in 85 countries.
Since 2012, Vered has been an ambassador and speaker for the Australian National Breast Cancer Foundation.
Carlos M. Nunez, M.D., was appointed ResMed’s chief medical officer in January 2017.
Prior to joining ResMed, he was senior vice president of Medical Affairs at Becton, Dickinson and Company, leading the Office of Science, Medicine and Technology for its largest division; chief medical officer at CareFusion, where he built and led a global team that provided company-wide medical oversight; and chief physician executive at Picis, Inc. (a medical informatics leader that later joined the Optum division of UnitedHealth Group), providing medical leadership and clinical direction for its corporate and commercial strategies.
Before working in the medtech industry, Carlos was a practicing anesthesiologist, intensivist, and hospitalist; director of critical care research, informatics, and analytics; and the Duke University educational affiliation at Carolinas Medical Center NorthEast.
Carlos also serves as chair of the Consumer Technology Association’s Health division since January 2023 and board member of Primasun, a joint venture of ResMed and Verily (an Alphabet company) that is developing more efficient and equitable digital pathways toward improving people’s sleep.
Carlos received his medical doctorate from the University of Miami School of Medicine, where he also completed his postgraduate training in anesthesiology, critical care medicine and clinical research.
Hemanth Reddy was appointed ResMed’s chief strategy officer in September 2013, responsible for the company’s global corporate strategy and corporate development functions.
Prior to joining ResMed, Hemanth was a strategy consultant for 14 years, advising on a range of issues including corporate strategy, business unit strategy, portfolio strategy, and inorganic growth strategy across consumer products, high tech, biotech and other industries. He was most recently a principal with Monitor Deloitte, Deloitte Consulting’s Strategy practice, co-leading its San Francisco office. Prior to Deloitte, he was a partner with Monitor Group where he co-led corporate finance activities in North America and shared leadership responsibility for Monitor’s Mergers & Acquisitions advisory practice. Before Monitor Group, he was an investment banker with Donaldson, Lufkin & Jenrette (DLJ) in New York, where he advised clients in structuring and executing debt and equity offerings, as well as private equity transactions.
Hemanth holds a Master of Business Administration in Finance, Strategy and Marketing from Northwestern University’s Kellogg School of Management and a bachelor’s in computer science from Cornell University’s College of Engineering.
Amy Wakeham was appointed ResMed’s Chief Investor Relations Officer in November 2023, responsible for executive oversight and leadership of stakeholder engagement across global financial and investor communities. She previously served as Chief Communications Officer and joined ResMed in June 2018 as vice president of Corporate Communications and Investor Relations.
Amy has over 10 years of practical experience in key finance roles in treasury and accounting, in addition to more than 15 years of experience leading integrated communications teams. Prior to joining ResMed, she served as vice president of Investor Relations & Communications for Integer Holdings Corporation (NYSE: ITGR) and as senior director of Investor Relations & Corporate Communications for Maxwell Technologies (NASDAQ: MXWL). Earlier in her career, she was vice president of Corporate Communications & Investor Relations for Leap Wireless (until its acquisition by AT&T in 2014) and held roles in finance, treasury, and accounting at Leap as well. She started her career in public accounting with Ernst & Young.
Amy also serves on the steering committee of the National Investor Relations Institute’s Senior Roundtable, as a volunteer with Girl Scouts of San Diego since 2018, and as a volunteer fundraiser for the Leukemia and Lymphoma Society since 2012.
Amy holds a Bachelor of Science degree in accounting from Pepperdine University and a Master of Business Administration from the University of California at Irvine.
Jim Ellis was appointed ResMed Chief Compliance Officer in 2018, responsible for establishing the company’s corporate compliance department and overseeing the global compliance function.
Before joining ResMed, Jim was Vice President and Associate General Counsel and head of the global litigation, legal regulatory and compliance for Hill-Rom Holdings, Inc., a publicly traded global medical technologies company acquired by Baxter International in 2021. While at Hill-Rom, Jim also served as Chief Compliance Officer and worked extensively on expanding the compliance function globally. He spent nearly a decade as the Chief Regulatory Counsel at Hospira, Inc., a leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, acquired by Pfizer in 2015. During his time at Hospira, Jim was one of a select few industry representatives who worked on developing the U.S. pathway for biosimilar medicines under the Biologics Price Competition and Innovation Act.
Jim began his legal career in private practice and was a litigation partner at the Chicago law firm of Bell, Boyd & Lloyd (now K&L Gates), where he concentrated in general commercial litigation and represented regulated industry clients adverse to various governmental agencies, including the Department of Health & Human Services, Securities & Exchange Commission, Federal Trade Commission, and the Food & Drug Administration.
In addition to the law, Jim studied aeronautical engineering at Purdue University and is a graduate of the University of Illinois. He also served as an independent member of the regulatory committee of the Board of Directors for Nurx, Inc., now part of Thirty Madison.
Todd Friedman was appointed ResMed Chief Information Security Officer (CISO) in April 2015, responsible for enterprise security, application security, and global risk and compliance. He oversees the team that sets information security strategy, which includes supervision of application security operations, IT risk management, application and product security, and cloud security, among other aspects of information security.
In addition to his CISO role, Todd previously led Privacy and served as co-Chief Information Officer (CIO) for over a year at ResMed.
Todd has more than 20 years of experience in information risk and security management and information technology leadership in the healthcare, consumer product, entertainment, and insurance industries. Prior to joining ResMed, Todd was the CISO of Mattel. His experience includes a stint as SVP and CISO of Universal Music Group, the world largest music company.
Todd is active in the cybersecurity community. He serves on the governance board of Evanta; is a member of Security 50, a subset of the executive development and networking community G100; and participates in panels where he shares security knowledge. Todd also is on the advisory board of CyberStarts and NetSkope.
A native of Los Angeles, he holds an MBA from the University of California Los Angeles (UCLA) and a bachelor of arts from UC San Diego. Todd maintains certifications as a Certified Information Systems Security Professional (CISSP), Certified Information Security Manager (CISM), and Certified Information Privacy Professional (CIPP), as well as being Certified in Risk and Information Systems Control (CRISC).
Alastair Robertson was appointed ResMed Chief Information Office (CIO) in February 2024, responsible for shaping ResMed’s enterprise architecture and corporate systems and influencing the future of digital healthcare by overseeing the company’s technology-driven, market-leading vision in strategic alignment with business objectives, customer experience, and revenue goals.
Alastair has more than 20 years of experience in digital and technology leadership, spanning across multiple industries, including telecommunications, media, consulting, and pharmaceutical industries. He has a passion for building and scaling engineering teams, with deep expertise in operational model design and enterprise ways of working. Before joining ResMed, Alastair was the Executive General Manager of Customer Technology for Insurance Australia Group. Prior to this role, he served as the CIO at Qantas Loyalty, and prior to that in technology leadership at Fox Sports Australia, Seven West Media, Boston Consulting Group, and GlaxoSmithKline.
Alastair has a Bachelor of Science in Information Technology from the University of Salford in the UK. He is a passionate champion of what we call belonging, inclusion, and diversity for success here at ResMed, and he serves as an active mentor and advisor for emerging talent.
Shane Azzi was appointed as ResMed Chief Supply Chain Officer (CSCO) on August 1, 2024, responsible for architecting and leading the next generation of supply chain operations for ResMed. Shane will oversee ResMed’s global supply, manufacturing and engineering, and distribution processes. While optimizing supply chain efficiency and productivity in alignment with strategic business goals, Shane will also drive innovation and collaboration to improve our supply chain resilience, responsiveness, and agility – all attributes we need to manage risk in a complex global market. He is a results-oriented leader with a passion for developing teams, delivering large-scale supply chain operation transformation, and aligning activities to deliver value across the entire end-to-end supply chain.
Bringing to ResMed a wealth of knowledge and experience cultivated over more than 20 years in senior positions, Shane has worked across a diverse group of companies respected for tightly integrated and high-performing supply chains. Before joining ResMed, Shane was the Chief Global Supply Chain Officer at Hasbro. Prior to this role, he served in several senior supply chain leadership roles with Kimberly-Clark, most recently as Global Chief Supply Chain Officer. He also previously led the supply chain team at Mars as Global Vice President, Supply Chain.
Shane has a Bachelor of Management and Professional Studies from Southern Cross University in Lismore, Australia, and holds a Graduate Diploma of Business, Integrated Logistics Management from the Royal Melbourne Institute of Technology.
.jpg)
